



(12) Translation of  
European patent specification

(11) NO/EP 2991637 B1

NORWAY

(19) NO  
(51) Int Cl.  
*A61K 31/137 (2006.01)*  
*A61K 45/06 (2006.01)*  
*A61P 25/08 (2006.01)*

**Norwegian Industrial Property Office**

---

(21)	Translation Published	2018.08.06
(80)	Date of The European Patent Office Publication of the Granted Patent	2018.03.07
(86)	European Application Nr.	14724037.8
(86)	European Filing Date	2014.05.01
(87)	The European Application's Publication Date	2016.03.09
(30)	Priority	2013.05.03, US, 201313887014
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	Katholieke Universiteit Leuven, K.U. Leuven R&D Waaistraat 6 Box 5105, 3000 Leuven, BE-Belgia University Hospital Antwerp, Wilrijkstraat 10, 2650 Edegem, BE-Belgia
(72)	Inventor	CEULEMANS, Berten, Rode Kruislaan 26, 2390 Westmalle, BE-Belgia LAGAE, Lieven, Boslaan 15A, 3050 Oud Heverlee, BE-Belgia
(74)	Agent or Attorney	BRYN AARFLOT AS, Stortingsgata 8, 0161 OSLO, Norge

---

(54)	Title	<b>FENFLURAMINE FOR USE IN THE TREATMENT OF DRAVET SYNDROME</b>
(56)	References Cited:	JP-A- H05 310 564, BERTEN CEULEMANS ET AL: "Successful use of fenfluramine as an add-on treatment for Dravet syndrome", EPILEPSIA, vol. 53, no. 7, 3 May 2012 (2012-05-03), pages 1131-1139, XP055123152, ISSN: 0013-9580, DOI: 10.1111/j.1528-1167.2012.03495.x cited in the application, Anonymous: "MacReportMedia - Brabant Pharma Reports Two-Year Follow-Up Data From a 19-year Observational Study Using Low-Dose Fenfluramine for the Treatment of Dravet Syndrome", , 25 November 2013 (2013-11-25), XP055123161, Retrieved from the Internet: URL: <a href="http://www.macreportmedia.com/ViewSubmission.aspx?submissionRequest=25655">http://www.macreportmedia.com/ViewSubmission.aspx?submissionRequest=25655</a> [retrieved on 2014-06-13], MEADOR K J: "Seizure reduction with fluoxetine in an adult woman with Dravet syndrome", EPILEPSY & BEHAVIOR CASE REPORTS, ELSEVIER BV, NL, vol. 2, 1 January 2014 (2014-01-01), pages 54-56, XP008169941, ISSN: 2213-3232, DOI: <a href="http://DX.DOI.ORG/10.1016/J.EBCR.2014.03.001">HTTP ://DX.DOI.ORG/10.1016/J.EBCR.2014.03.001</a> , CEULEMANS B. ET AL.: "Successful use of Fenfluramine as add-on treatment in Dravet syndrome: a two year prospective follow up", EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, vol. 17, 011-1866, 1 September 2013 (2013-09-01), XP55123344, US ISSN:

1090-3798, DOI: 10.1016/S1090-3798(13)70013-8, K Gentsch ET AL: "Laboratory Research Fenfluramine Blocks Low-Mg<sup>2+</sup>-Induced Epileptiform Activity in Rat Entorhinal Cortex", *Epilepsia*, 1 January 2000 (2000-01-01), pages 925-928, XP055123170, Retrieved from the Internet: URL:<http://onlinelibrary.wiley.com/store/10.1111/j.1528-1157.2000.tb00273.x/asset/j.1528-1157.2000.tb00273.x.pdf?v=1&t=hwd6ipvs&s=4597c5b395f43216016ee3e5eea1c52bb7f99d62> [retrieved on 2014-06-13]

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

## PATENTKRAV

1. Formulering som omfatter fenfluramin eller et farmasøytisk akseptabelt salt derav for anvendelse ved behandling av Dravets syndrom,  
hvor formuleringen er for oral administrering, og  
5 hvor behandlingen omfatter administrering av fenfluramin som en monoterapi som det eneste terapeutiske midlet.
2. Formuleringen for anvendelse ifølge krav 1, hvor behandlingen omfatter behandling av en pasient diagnostisert med Dravets syndrom, som utviser en mutasjon i ett av, noen av  
10 eller alle genene valgt fra gruppen som består av SCN1A, SCN1B, SCN2A, SCN3A, SCN9A, GABRG2, GABRD og PCDH19.
3. Formuleringen for anvendelse ifølge krav 1 eller krav 2, hvor dosen av fenfluramin er mindre enn 0,5 mg/kg/dag til 0,01 mg/kg/dag.  
15
4. Formuleringen for anvendelse ifølge ett av kravene 1 til 3, hvor formuleringen er en flytende formulering.